Rapport Therapeutics, Inc.
RAPP
$27.62
-$0.22-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.06% | 13.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.42% | 1.66% | |||
| Operating Income | -28.42% | -1.66% | |||
| Income Before Tax | -25.40% | -0.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.40% | -0.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.40% | -0.72% | |||
| EBIT | -28.42% | -1.66% | |||
| EBITDA | -28.64% | -1.66% | |||
| EPS Basic | -1.25% | 5.89% | |||
| Normalized Basic EPS | -1.26% | 5.90% | |||
| EPS Diluted | -1.25% | 5.89% | |||
| Normalized Diluted EPS | -1.26% | 5.90% | |||
| Average Basic Shares Outstanding | 23.85% | 7.02% | |||
| Average Diluted Shares Outstanding | 23.85% | 7.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||